PRESS RELEASE published on 09/02/2025 at 13:00, 3 months 3 days ago Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism Moderna, Inc. to present abstracts on mRNA therapeutics at the 2025 ICIEM including PA, MMA, and GSD1a programs in Kyoto, Japan. Company's first time presenting data for MMA and GSD1a Moderna Inc. MRNA Therapeutics ICIEM Abstracts Kyoto Japan
BRIEF published on 08/27/2025 at 19:29, 3 months 9 days ago Les vaccins Moderna contre la COVID-19 mis à jour approuvés par la FDA américaine Approbation De La FDA Moderne Vaccin Contre Le Covid-19 Variante Du SRAS-CoV-2 Spikevax Et MNEXSPIKE
BRIEF published on 08/27/2025 at 19:29, 3 months 9 days ago Moderna's Updated COVID-19 Vaccines Approved by U.S. FDA FDA Approval COVID-19 Vaccine Moderna SARS-CoV-2 Variant Spikevax And MNEXSPIKE
PRESS RELEASE published on 08/27/2025 at 19:24, 3 months 9 days ago Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 Moderna announces FDA approval for updated Spikevax® and mNEXSPIKE® COVID-19 vaccines targeting LP.8.1 variant to prevent severe outcomes. Vaccines available soon FDA Approval Moderna COVID-19 Vaccines Spikevax MNEXSPIKE
BRIEF published on 08/22/2025 at 15:30, 3 months 14 days ago Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine COVID-19 Vaccine Moderna Health Canada Approval Canadian Manufacturing Biomanufacturing Leadership
BRIEF published on 08/22/2025 at 15:30, 3 months 14 days ago Moderna reçoit l'approbation de Santé Canada pour son vaccin contre la COVID-19 mis à jour Moderne Vaccin Contre Le Covid-19 Fabrication Canadienne Approbation De Santé Canada Leadership En Bioproduction
PRESS RELEASE published on 08/22/2025 at 15:25, 3 months 14 days ago Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 Moderna's Spikevax COVID-19 vaccine for SARS-CoV-2 LP.8.1 variant authorized in Canada, with all 2025 doses produced domestically. Leadership in biomanufacturing highlighted COVID-19 Vaccine Canada Moderna Spikevax Biomanufacturing
BRIEF published on 08/21/2025 at 13:05, 3 months 15 days ago Moderna participera aux principales conférences de septembre 2025 Conférences D'investisseurs Moderne Webcast En Direct Médecine À Base D'ARNm Présentation Des Soins De Santé
BRIEF published on 08/21/2025 at 13:05, 3 months 15 days ago Moderna to Participate in Major September 2025 Conferences Investor Conferences MRNA Medicine Moderna Live Webcast Healthcare Presentation
PRESS RELEASE published on 08/21/2025 at 13:00, 3 months 15 days ago Moderna to Present at Upcoming Conferences in September 2025 Moderna, Inc. to participate in upcoming investor conferences. The company's innovative mRNA technology redefines medicine creation, focusing on infectious diseases, oncology, and more Investor Conferences Healthcare COVID-19 Vaccine MRNA Technology Moderna
Published on 12/05/2025 at 20:25, 45 minutes ago The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others
Published on 12/05/2025 at 20:15, 55 minutes ago When Proof Becomes Infrastructure, Markets Rewrite the Story (NASDAQ: SMX)
Published on 12/05/2025 at 19:50, 1 hour 20 minutes ago Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 19:20, 1 hour 50 minutes ago The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 2 hours 25 minutes ago Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:58, 2 hours 11 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:15, 2 hours 54 minutes ago Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:46, 3 hours 23 minutes ago Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:18, 3 hours 52 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 3 hours 52 minutes ago The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 5 hours 59 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 5 hours 59 minutes ago Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 7 hours 11 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
